Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)

Thymoma Clinical Trial

— RELEVENT  

Official title:

Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03921671
• Other study ID #: NT-TET1-7371
• Secondary ID: 2017-004494-13
• Status: Recruiting
• Phase: Phase 2
• Start date: November 1, 2018
• Est. completion date: July 16, 2022

Study information

• Verified date: November 2020
• Source: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
• Contact: Irene De Simone
• Phone: 02 3901 4661
• Email: irene.desimone[@]marionegri.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicentric study. All patients with TET (thymic epithelial tumors) of any histological type will participate in the study. This is an open-label phase 2 study that will follow a Green-Dahlberg 2-stage design whose objective is to evaluate the activity and safety of the combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with relapsed and / or metastatic thymic carcinoma/ thymoma B3, in the first line (RELEVENT trial).

Description:

Clinical and quality of life data will be collected for all treated patient. Based on the histological evaluation performed by each participating center, patients will be screened for inclusion in one of the four studies, based on the following criteria: - TOPS study only: all patients with A, AB, B1, B2, B3 without areas of carcinoma histology, diagnosed during or after 2018, that do not have a fresh tissue sample and screen failures of the RELEVENT and BIOTET study; - TRY registry: all patients with TETs diagnosed, treated or followed from 2010 to 2017 included (retrospective data collection); - BIOTET only: all patients with A, AB, B1, B2, B3 without areas of histology of the carcinoma that have a fresh tissue sample; - RELEVENT only: all patients with thymoma B3 and areas of carcinoma and pa-tients with thymic carcinoma who do not have a fresh tissue sample. Patients with thymic carcinoma or thymoma B3 with areas of carcinoma will receive a centralized pathological review of the tumour block or slides and will be screened to participate in the Phase II RELEVENT pharmacological study.Histological diagnosis will be confirmed before screening.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: July 16, 2022
• Est. primary completion date: October 9, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. provision of written informed consent before treatment initiation

2. pathologically confirmed thymic carcinoma and B3 thymomas, with areas of carcinoma locally advanced as per central histological revision, recurrent and/or metastatic, not amenable to potentially curative treatments.

3. age>= 18 years old

4. provision of archival or fresh tissue (block or at least 15 charged slides 4µM of thickness).

5. Blood and plasma sampling at baseline and at first clinical revaluation

6. measurable disease (defined according to Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1);7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

8. adequate hematologic function, as evidenced by an absolute neutrophil count (ANC) =1500/µL, haemoglobin =9 g/dL (5.58 mmol/L), and platelets =100,000/µL; 9. adequate coagulation function as defined by International Normalized Ratio (INR) = 1.5, and a partial thromboplastin time (PTT) = 5 seconds above the ULN (unless receiving anticoagulation therapy). Patients receiving warfarin must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to first dose of protocol therapy 10. adequate hepatic function as defined by a total bilirubin =1.5times the upper limit of normal (ULN), (Except for patients with Gilbert's syndrome who may only be included in the total bilirubin is < 3.0 x ULN or direct bilirubin < 1.5 x ULN) and aspartate transaminase (AST) and alanine transaminase (ALT) = 3.0 times the upper limit of normal (or 5.0 times the ULN in the setting of liver metastases) 11. adequate renal function as defined by a serum creatinine =1.5 times the ULN, or creatinine clearance (measured via 24-hour urine collection) =40 mL/minute (that is, if serum creatinine is >1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed). The patient's urinary protein is =1+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is =2+, a 24-hour urine collection for protein must demonstrate <1000 mg of protein in 24 hours to allow participation in this protocol).

12. sexually active patients, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods). Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose of protocol therapy. 13. Prior radiation therapy is allowed.

• In case of chest radiotherapy a 28 days interval is needed between the end of the radiation treatment and the start of treatment .
• In the case of focal or palliative radiation treatment a 7 days interval is needed from last radiation treatment to start of treatment (and provided that 25% or less of total bone marrow had been irradiated).
• In the case of CNS radiation a minimum of 14 days interval is needed from the end of radiation treatment to start of treatment.

Exclusion Criteria:

1. previous systemic treatment for locally advanced/metastatic thymic carcinoma/B3 thymomas; patients treated in the neoadjuvant or adjuvant setting can be enrolled after discussion with PI

2. untreated CNS metastases. Patients with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) ending at least 2 weeks prior to start of treatment, or after surgical resection performed at least 28 days prior to start of treatment. The patient may have no evidence of Grade =1 CNS haemorrhage based on pre-treatment Magnetic Resonance Imaging (MRI) or IV contrast CT scan (performed within 28 days before start of treatment)

3. any Grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy

4. peripheral neuropathy = G2History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") during the 3 months prior to first dose of protocol therapy.

5. patient has experienced hemoptysis (defined as bright red blood or = 1/2 teaspoon) within 2 months prior to first dose of protocol therapy

6. radiographic evidence of intra-tumour cavitation, radiologically documented evidence of major blood vessel invasion or encasement by cancer

7. history of uncontrolled hereditary or acquired thrombotic disorder

8. The patient has:

• cirrhosis at a level of Child-Pugh B (or worse) or
• cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis.

9. clinically relevant congestive heart failure (NYHA II-IV) or symptomatic or poorly controlled cardiac arrhythmia

10. The patient has experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to first dose of protocol therapy.uncontrolled or poorly-controlled hypertension (>160 mmHg systolic or > 100 mmHg diastolic for >4 weeks) despite standard medical management.

11. serious or no healing wound, ulcer, or bone fracture within 28 days prior to start of treatment

12. significant bleeding disorders, vasculitis, or experienced grade 3/4 gastrointestinal (GI) bleeding within 3 months prior to start of treatment

13. history of GI perforation and / or fistulae within 6 months prior to start of treatment

14. bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhoea

15. peripheral neuropathy =grade 2 (NCI-CTCAE v 4.0)

16. serious illness or medical condition(s) including, but not limited to, the following:

-Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)- related illness.

• Active or uncontrolled clinically serious infection.
• Previous or concurrent malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumours treated curatively and without evidence of recurrence for at least 3 years prior to start of treatment.
• Uncontrolled metabolic disorders or other non-malignant organ or systemic diseases or secondary effects of cancer that induce a high medical risk and/or make assessment of survival uncertain.
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient ineligible for entry into this study.
• significant third-space fluid retention (for example, ascites or pleural effusion), and is not amenable for required repeated drainage

17. known allergy or hypersensitivity reaction to any of the treatment components

18. known history of active drug abuse

19. patient is pregnant or breastfeeding

20. major surgery within 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement within 7 days prior to first dose of protocol therapy

21. elective or planned major surgery to be performed during the course of the clinical trial

22. patient is receiving concurrent treatment with other anticancer therapy

23. patient is receiving chronic antiplatelet therapy, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg/day) is permitted.

Related Conditions & MeSH terms

• Carcinoma
• Thymic Carcinoma
• Thymoma
• Thymus Neoplasms

Intervention

Combination Product:
• Ramucirumab
Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed and / or metastatic, in the first line.

Locations

Country	Name	City	State
Italy	Fondazione IRCCS Istituto Nazionale dei Tumori	Milan

Sponsors (1)

Lead Sponsor	Collaborator
Marina Garassino

Country where clinical trial is conducted

Italy, 

References & Publications (13)

Benveniste MF, Korst RJ, Rajan A, Detterbeck FC, Marom EM; International Thymic Malignancy Interest Group. A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thy — View Citation

Berruti A, Borasio P, Gerbino A, Gorzegno G, Moschini T, Tampellini M, Ardissone F, Brizzi MP, Dolcetti A, Dogliotti L. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution ex — View Citation

Enkner F, Pichlhöfer B, Zaharie AT, Krunic M, Holper TM, Janik S, Moser B, Schlangen K, Neudert B, Walter K, Migschitz B, Müllauer L. Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets. Pathol — View Citation

Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J. 2001 Jan;77(903):24-8. Review. — View Citation

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH. Antiemetics: American Society of Clinical Oncology Clinical Practice — View Citation

Hirai F, Yamanaka T, Taguchi K, Daga H, Ono A, Tanaka K, Kogure Y, Shimizu J, Kimura T, Fukuoka J, Iwamoto Y, Sasaki H, Takeda K, Seto T, Ichinose Y, Nakagawa K, Nakanishi Y; West Japan Oncology Group. A multicenter phase II study of carboplatin and pacli — View Citation

Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008 Feb;65(2):205-10. doi: 10.1001/archneurol.2007.46. — View Citation

Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, Loehrer PJ Sr. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011 May 20;29(15):2060-5. doi: 10.1200/JCO.2010.32.9607. Epub 2011 Apr 18. — View Citation

López-García F, Amorós-Martínez F, Sempere AP. [A reversible posterior leukoencephalopathy syndrome]. Rev Neurol. 2004 Feb 1-15;38(3):261-6. Review. Spanish. — View Citation

Marinella MA, Markert RJ. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J. 2009 Dec;39(12):826-34. doi: 10.1111/j.1445-5994.2008.01829.x. Epub 2008 Nov 3. — View Citation

Okuma Y, Saito M, Hosomi Y, Sakuyama T, Okamura T. Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol. 2015 Feb;141(2):3 — View Citation

Pagano M, Sierra NM, Panebianco M, Rossi G, Gnoni R, Bisagni G, Boni C. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations. Anticancer Res. 2014 Sep;34(9):5105-10. — View Citation

Schwartz RB. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996 Jun 27;334(26):1743; author reply 1746. — View Citation

* Note: There are 13 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Comprehensive analysis of tumor mutational status on paraffin-embedded tissue	Targeted re-sequencing of genes mutated in TETs in order to define the prognostic role of somatic mutations and their potential association to prognosis or response to therapy	4 years
Other	Comprehensive analysis of single nucleotide polymorphism in blood	Genome-wide approach using a platform able to investigate more than 4 million SNP in order to find potential association with prognosis or response to therapy	4 years
Other	Analysis of circulating micro-RNA	Analysis of micro-RNA in plasma and their evaluation as possible biomarker associated with prognosis or response to therapy	4 years
Other	Quality of life analysis through collection of Patients Reported Outcome (PROs)	Web based PROs will be administered at each visit and data about compliance will be collected	4 years
Primary	Best tumour response (CR+PR)	Objective tumor response will be assessed according to RECIST 1.1.	6 months
Secondary	Progression Free Survival (PFS)	Disease progression will be established as the radiological progression according to RECIST 1.1 or through clinical assessment in case radiological evaluation is not feasible or as death from any cause due to clinical condition. PFS will be estimated through Kaplan-Meier method	4 years
Secondary	Overall Survival (OS)	OS will be estimated through Kaplan-Meier method	4 years